Imaging test for detecting and grading myelofibrosis in adults
Tests a PET/CT scan using 68Ga-FAPI to detect and grade myelofibrosis in adults.
Plain-language title generated from the registry record
Registry title: 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
Key facts
- Where
- Xiamen, ChinaSee the site
Where in China
- Bing XuXiamen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Xiamen University
- Trial code
- NCT06151119
- Record updated
- 19 February 2025
- Original description
To evaluate the diagnostic efficacy of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades.Read full original descriptionShow less
A Study to Evaluate 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
To evaluate the diagnostic efficacy of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades.
To evaluate the diagnostic efficacy of 68Ga FAPIPET/CT imaging in patients with myelofibrosis, compared with conventional CT.
Inclusion: Age ≥18 years old; Cohort 1: Patients with suspected or confirmed myelofibrosis; Cohort 2: Patients with primary/secondary myelofibrosis who were not treated with ruxolitinib; The expected survival time is over 3 months; Voluntarily sign informed consent; Willing and able to follow the research protocol; The subject must be able to lie on the scanning bed for 20 minutes.
Exclusion: Patients who can not tolerate intravenous drug administration (such as needle fainting and blood fainting history); Workers who are exposed to radiation for a long period of time; Participating in other interventional clinical trials within 1 month before screening; Known allergic history to 68Ga FAPI or its excipients; Serious diseases of the heart, kidney, lung, blood vessel, nervous system, mental system, immune deficiency diseases and hepatitis/cirrhosis; Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy due to other cancers; Those who are not suitable for or unable to complete imaging tests such as PET due to special reasons, including claustrophobia and radiophobia; pregnant and lactating women; There are other circumstances that the researcher thinks are not suitable for participating in this study.